Evidence map›Paper›PMID 32139545›Full record

ArticleScience (New York, N.Y.)2020

Pervasive functional translation of noncanonical human open reading frames.

Jin Chen, Andreas-David Brunner, J Zachery Cogan, James K Nuñez, Alexander P Fields, Britt Adamson, Daniel N Itzhak, Jason Y Li, Matthias Mann, Manuel D Leonetti and 1 more

Open access · greenAbstract read
In one paragraph

Article in Science (New York, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 408 papers.

0numbers the graph read from it
0cells of the map it votes in
408citing papers in PubMed
55.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

408 citing papers in PubMed, 660 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. The diverse functions of viral microproteins.bioRxiv : the preprint server for biology · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

348 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Jin ChenDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA.ORCID 0000-0002-6634-4397
Andreas-David BrunnerDepartment of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried 82152, Germany.ORCID 0000-0002-2733-7899
J Zachery CoganDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA.
James K NuñezDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA.ORCID 0000-0002-7396-6119
Alexander P FieldsDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA.
Britt AdamsonDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA.ORCID 0000-0002-9451-5819
Daniel N ItzhakCell Atlas Initiative, Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.ORCID 0000-0002-4720-273X
Jason Y LiCell Atlas Initiative, Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.
Matthias MannDepartment of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried 82152, Germany.ORCID 0000-0003-1292-4799
Manuel D LeonettiCell Atlas Initiative, Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.ORCID 0000-0002-4881-405X
Jonathan S WeissmanDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA. jonathan.weissman@ucsf.edu.ORCID 0000-0003-2445-670X
Howard Hughes Medical Institute · USChan Zuckerberg Initiative (United States) · USMax Planck Institute of Biochemistry · DENovo Nordisk Foundation · DK

Funding

Center for Genomic Editing and Recording: Development and Application of Next-Generation Genome and Epigenome Editing Methods to Advance the Study and Treatment of Human DiseaseRM1HG009490 · NHGRI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI Brittany S. Adamson, Martin Joseph Ankrah Aryee · 2017 to 2026
$22.7M
Defining the regulatory roles of alternative ribosome initiation and novel peptidesR00GM134154 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI CHEN, JIN · 2021 to 2022
$416k
Defining the regulatory roles of alternative ribosome initiation and novel peptidesK99GM134154 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, JIN · 2019 to 2020
$150k
NHGRI NIH HHS RM1 HG009490NIGMS NIH HHS K99 GM134154NIGMS NIH HHS R00 GM134154
6 · The paper itself

Abstract

Ribosome profiling has revealed pervasive but largely uncharacterized translation outside of canonical coding sequences (CDSs). In this work, we exploit a systematic CRISPR-based screening strategy to identify hundreds of noncanonical CDSs that are essential for cellular growth and whose disruption elicits specific, robust transcriptomic and phenotypic changes in human cells. Functional characterization of the encoded microproteins reveals distinct cellular localizations, specific protein binding partners, and hundreds of microproteins that are presented by the human leukocyte antigen system. We find multiple microproteins encoded in upstream open reading frames, which form stable complexes with the main, canonical protein encoded on the same messenger RNA, thereby revealing the use of functional bicistronic operons in mammals. Together, our results point to a family of functional human microproteins that play critical and diverse cellular roles.

Indexed as

Open Reading FramesRNA, MessengerCRISPR-Cas SystemsHumansOperonPeptidesProtein BiosynthesisRibosomesTranscriptomePeptidesRNA, Messenger

Identifiers

PMID32139545
PMCPMC7289059
OpenAlexW3010073072

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.